Literature DB >> 22298090

Association of helicobacter pylori dupA with the failure of primary eradication.

Seiji Shiota1, Lam Tung Nguyen, Kazunari Murakami, Akiko Kuroda, Kazuhiro Mizukami, Tadayoshi Okimoto, Masaaki Kodama, Toshio Fujioka, Yoshio Yamaoka.   

Abstract

GOALS: To determine whether the presence of dupA Helicobacter pylori (H. pylori) influences the cure rate of primary eradication therapy.
BACKGROUND: Several virulence factors of H. pylori have been reported to affect the efficacy of the eradication rate. However, no study has investigated whether the presence of dupA affects eradication failure. STUDY: The presence of dupA was evaluated in 142 H. pylori strains isolated from 142 patients with gastrointestinal diseases. Of these patients, 104 received primary eradication therapy for 1 week. The risk factors for eradication failure were determined using univariate and multivariate analyses.
RESULTS: Among 142 strains, 44 (31.0%) were dupA positive. There was no association between dupA status and gastroduodenal diseases (P>0.05). The clarithromycin (CLR) resistance rate was generally lower in the dupA-positive than in the dupA-negative group (20.4% vs. 35.7%, P=0.06). However, dupA prevalence was higher in the eradication failure group than in the success group (36.3% vs. 21.9%). Among the CLR-resistant H. pylori infected group, the successful eradication rate was significantly lower in patients infected with dupA-positive H. pylori than dupA-negative H. pylori (P=0.04). In multivariate analysis adjusted for age, sex, and type of disease, not only CLR resistance but also dupA presence was independent risk factors for eradication failure (adjusted odds ratio=3.71; 95% confidence interval,1.07-12.83).
CONCLUSIONS: Although CLR resistant was more reliable predictor, the presence of dupA may also be an independent risk factor for eradication failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298090      PMCID: PMC3296869          DOI: 10.1097/MCG.0b013e318243201c

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  25 in total

1.  Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study.

Authors:  R W van der Hulst; A van der Ende; F W Dekker; F J Ten Kate; J F Weel; J J Keller; S P Kruizinga; J Dankert; G N Tytgat
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

Review 2.  Control of gastric acid secretion in health and disease.

Authors:  Mitchell L Schubert; David A Peura
Journal:  Gastroenterology       Date:  2008-05-12       Impact factor: 22.682

3.  Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents.

Authors:  M L Grayson; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 4.  The role of antisecretory drugs in the treatment of Helicobacter pylori infection.

Authors:  W L Peterson
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

5.  pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism.

Authors:  R H Hunt
Journal:  Am J Gastroenterol       Date:  1993-04       Impact factor: 10.864

6.  Helicobacter pylori dupA and gastric acid secretion are negatively associated with gastric cancer development.

Authors:  Shinobu Imagawa; Masanori Ito; Masaharu Yoshihara; Hidetaka Eguchi; Shinji Tanaka; Kazuaki Chayama
Journal:  J Med Microbiol       Date:  2010-09-09       Impact factor: 2.472

7.  Helicobacter pylori antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales.

Authors:  Nicola C Elviss; Robert J Owen; Jacqueline Xerry; A Mark Walker; Kenneth Davies
Journal:  J Antimicrob Chemother       Date:  2004-07-08       Impact factor: 5.790

8.  Influence of Helicobacter pylori genotype on triple eradication therapy.

Authors:  Jian Jun Zhao; Jiang Bin Wang; Lei Yang; Yan Li
Journal:  J Gastroenterol Hepatol       Date:  2007-12       Impact factor: 4.029

9.  Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.

Authors:  V De Francesco; A Zullo; M Margiotta; S Marangi; O Burattini; P Berloco; F Russo; M Barone; A Di Leo; M F Minenna; V Stoppino; S Morini; C Panella; A Francavilla; E Ierardi
Journal:  Aliment Pharmacol Ther       Date:  2004-02-15       Impact factor: 8.171

10.  Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005.

Authors:  Intetsu Kobayashi; Kazunari Murakami; Mototsugu Kato; Seiichi Kato; Takeshi Azuma; Shin'ichi Takahashi; Naomi Uemura; Tsutomu Katsuyama; Yoshihiro Fukuda; Ken Haruma; Masaru Nasu; Toshio Fujioka
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

View more
  15 in total

1.  Investigation of Clarithromycin Resistance-Associated Mutations and Virulence Genotypes of Helicobacter pylori Isolated from Iranian Population: A Cross-Sectional Study.

Authors:  Helia Alavifard; Nasrin Mirzaei; Abbas Yadegar; Kaveh Baghaei; Sinéad Marian Smith; Amir Sadeghi; Mohammad Reza Zali
Journal:  Curr Microbiol       Date:  2020-11-30       Impact factor: 2.188

Review 2.  The significance of virulence factors in Helicobacter pylori.

Authors:  Seiji Shiota; Rumiko Suzuki; Yoshio Yamaoka
Journal:  J Dig Dis       Date:  2013-07       Impact factor: 2.325

Review 3.  Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.

Authors:  Mitsushige Sugimoto; Takahisa Furuta
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 4.  Helicobacter pylori infection in Japan.

Authors:  Seiji Shiota; Kazunari Murakawi; Rumiko Suzuki; Toshio Fujioka; Yoshio Yamaoka
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-01       Impact factor: 3.869

Review 5.  Effect of bacterial and host factors on Helicobacter pylori eradication therapy.

Authors:  Takahiro Uotani; Muhammad Miftahussurur; Yoshio Yamaoka
Journal:  Expert Opin Ther Targets       Date:  2015-08-06       Impact factor: 6.902

6.  Duodenal ulcer promoting gene 1 (dupA1) is associated with A2147G clarithromycin-resistance mutation but not interleukin-8 secretion from gastric mucosa in Iraqi patients.

Authors:  N R Hussein; I Tunjel; H S Majed; S T Yousif; S I Aswad; M S Assafi
Journal:  New Microbes New Infect       Date:  2015-03-04

Review 7.  Role of dupA in virulence of Helicobacter pylori.

Authors:  Amin Talebi Bezmin Abadi; Guillermo Perez-Perez
Journal:  World J Gastroenterol       Date:  2016-12-14       Impact factor: 5.742

8.  The association between vacA or cagA status and eradication outcome of Helicobacter pylori infection: A meta-analysis.

Authors:  Dan Wang; Qiuping Li; Yuehua Gong; Yuan Yuan
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

9.  Prevalence of Helicobacter pylori cagA and iceA Genes and Their Association with Gastrointestinal Diseases.

Authors:  Ashwak M F Abu-Taleb; Randa S Abdelattef; Amina A Abdel-Hady; Farida H Omran; Lobna A El-Korashi; Hoda Abdel-Aziz El-Hady; Ahmed M El-Gebaly
Journal:  Int J Microbiol       Date:  2018-04-05

Review 10.  Role of polymorphisms in genes that encode cytokines and Helicobacter pylori virulence factors in gastric carcinogenesis.

Authors:  Breno Bittencourt de Brito; Filipe Antônio França da Silva; Fabrício Freire de Melo
Journal:  World J Clin Oncol       Date:  2018-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.